Resistance to thyroid hormone (RTH) is a syndrome of reduced responsiveness of target
            tissues to thyroid hormone (TH). Patients with RTH are identified by persistent elevation
            of circulating free TH levels with non-suppressed serum TSH. The underlying genetic
            defect is usually, but not always, a mutation in the TRβ gene. The frequency of de
            novo mutations is estimated to 21%. The inheritance is autosomal dominant. The clinical
            presentation varies significantly among different patients. However, goiter and the
            absence of neuropsychological symptoms and metabolic sequences of TH excess belong
            to the common features of the syndrome.
         
         
            
         A 20 year old Caucasian female was admitted to the emergency department with palpitations.
            Her initial ECG showed supraventricular tachycardia. After administration of 5 mg
            metoprolol iv a sinus rhythm with heart rate of 85 bpm was documented. Initial laboratory
            findings revealed secondary hyperthyroidism. Additional blood tests revealed hyperlipidemia.
            The pituitary MRI discovered a lesion of 4 mm in the adenohypophysis. Symptoms and
            signs of hypopituitarism or overproduction of pituitary hormones were absent. TRH
            stimulation test led to adequate TSH response. Moreover, SHBG and α-GSU/TSH molar
            ratio were within normal values, ruling out a TSH-producing adenoma. Genetic analysis
            of TRβ gene identified a novel mutation in the 1st mutational cluster in the T3-binding domain of TRβ gene (c.1355C>G (p.Pro452Arg)). Unlike certain polymorphisms of deiodinases, this mutation was not identified
            in the genetic analysis of the family members, demonstrating a sporadic, de novo mutation
            of TRβ gene. Therapy with TRIAC (initial dosis 0.35 mg/day, gradually increasing to
            1.4 mg/day) led to normalization of TSH and cholesterol levels with simultaneous decrease
            in the fT4 levels. Furthermore, it could be documented a fall of the initially increased
            TTSI after administration of TRIAC.
         
         
            
         In patients with TRβ gene mutations and pituitary incidentalomas the differential
            diagnosis of the secondary hyperthyroidism might be challenging.